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ABSTRACT: Matrix metalloproteinases (MMPs) are central to cancer development and metastasis. They are highly active 
in the tumour environment and absent or inactive in normal tissues; therefore they represent viable targets for cancer 
drug discovery. In this study we evaluated in silico docking to develop MMP-subtype-selective tumour-activated pro-
drugs. Proof of principle for this therapeutic approach was demonstrated in vitro against an aggressive human glioma 
model, with involvement of MMPs confirmed using pharmacological inhibition.  
 
 
INTRODUCTION 
Matrix Metalloproteinases (MMPs) are zinc-dependent 
endoproteases central to digestion of extracellular matrix 
(ECM) and pericellular proteins involved in regulation of 
many normal physiological processes including tissue 
growth and embryogenesis.1-5 Their activity is regulated 
by both post-secretion zymogenic activation and inhibi-
tion by endogenous inhibitors termed TIMPs (tissue in-
hibitor of metalloproteinase).6 However, dysregulation of 
MMP expression and unbalanced endoproteolytic activity 
of specific MMPs is a major contributor to many degrada-
tive diseases including arthritis, cancer, cardiovascular 
disease, inflammatory disorders, and neurodegenera-
tion,5,7-9 thus making them attractive drug targets.2, 10, 11  
In the last two decades significant drug discovery effort 
was focused on inhibition of MMPs as a strategy to pre-
vent tumour invasion and subsequent tumour metasta-
ses.12 As a result the pharmaceutical industry produced a 
number of well tolerated orally active MMP inhibitors 
(MMPi).13 These agents were largely peptidomimetic zinc-
binding hydroxamates, based upon an MMP peptide sub-
strate.2,14,15 Although many of these inhibitors progressed 
to late stage clinical trials against metastatic cancer, lim-
ited clinical success was seen due to a lack of inhibitor 
MMP-subtype specificity and insufficient knowledge 
about the complexity of the disease biology.2,16,17 Several 
additional strategies have been evaluated over recent 
years, including development of inhibitors exploiting the 
enzymatic transition state,2,18 inhibitors binding enzyme 
cavity subsites,19 or alternative zinc chelation groups.2 
Generation of MMP subfamily-selective inhibitors still 
proves elusive however, because of the broad structural 
similarity of their active site, substrate complexity, and 
identification of specific MMPs as anti-targets.2,17 
In contrast to inhibition of MMP function, exploitation 
of the MMP-mediated proteolysis within diseased tissues 
has also been investigated as a diagnostic and prognostic 
approach. These studies used activity-based probes com-
prising a ‘broad-spectrum’ or selective MMP-cleavable 
peptide labelled with a quenched fluorophore or imaging 
moiety.20,21 In this approach, elevated MMP activity in the 
diseased tissue results in activation of the probe via selec-
tive cleavage of the peptide and release of the contrast 
agent, facilitating imaging and quantification of MMP 
activity.20,21  
In line with the MMP-activated probe-based approach-
es, elevated activity of MMPs within diseased tissue has 
also been explored as a strategy for conversion of a non-
toxic peptide-conjugated prodrug into a potent therapeu-
tic entity within the disease site. The advantage of this 
approach is dose intensification and reduced systemic 
drug exposure.1,22-26 A requirement for success in activity-
probes, prodrugs, or theranostic approaches is MMP-
selectivity through incorporation of MMP-subtype unique 
(e.g. MMP-2 or MMP-9) peptide sequences and subse-
quent disease-selective activation. 
The rationale for this study is to exploit the MMP bind-
ing subsites and modify the substrate residues to produce 
a prodrug selective for MMP-2 over MMP-9, and create a 
robust approach which could be exploited for develop-
 ment of endoprotease-activated diagnostic probes and 
therapeutics. Visualising and quantifying binding prefer-
ences and motifs can provide valuable insight into the 
structural determinants of substrate selectivity and enable 
MMP-targeted drug development.27 In order to achieve 
this the following steps were undertaken; definition of the 
catalytic domains within the relevant MMPs through in 
silico study, docking of known MMP-selective sequences 
to highlight key catalytic binding determinants, subse-
quent rational design of novel MMP-selective prodrugs, 
and in vitro confirmation of MMP-selectivity and thera-
peutic proof-of-concept. In this work a reiterative ap-
proach using in silico proteolytic docking coupled to in 
vitro biochemical assessment have been applied to enable 
the development of prodrugs that are selectively activated 
by MMP-2 over MMP-9, the closely related gelatinase 
family members. The availability of three-dimensional 
crystal structures of MMPs allowed us to critically exam-
ine the differences existing between the catalytic domains 
of the MMP-2 (PDB ID: 1QIB) and MMP-9 (PDB ID ID: 
1GKC).28 This allowed for successful development of in 
silico models of MMP-2 and MMP-9. The in silico model 
was able to accurately predict known cleavage sites on 
substrates and prodrugs by MMPs, thus enabling rational-
ized design of an MMP-2 selective peptide.  
RESULTS AND DISCUSSION 
The catalytic domain of MMPs consists of five β-sheet 
strands and three α-helixes. The catalytic centre compris-
es of a catalytic zinc ion coordinated by three histidine 
residues and a glutamic acid.28 The specificity loop within 
the catalytic site of MMPs shows the largest structural 
differences, as visualised for MMP-2 and MMP-9 in Figure 
S1. The overall folding of MMP-2 and MMP-9 resemble 
those of other MMPs, which is expected based on their 
structural similarity (Figure S1).29 The cavity of S1’ pockets 
in MMPs are well-suited to accommodate a wide-range of 
hydrophobic residues, with the main functional difference 
between MMP subtypes lying in this region. In MMP-9, 
residues 421 – 423 form the wall of the binding pocket and 
the specificity loop is formed by the residues 424 – 430. 
Arg424 is present at the bottom of S1’ pocket and closes 
off the end. Arg424 is therefore responsible for making 
the pocket cavity smaller in MMP-9 than in MMP2 (Fig-
ure S1). Whereas in MMP-2, the external wall of the S1’ 
pocket is largely formed by Thr227 – Phe232 specificity 
residues, creating a deeper pocket. These differences can 
potentially be exploited for rational design of MMP-
selective substrates/conjugates. 
To probe the selective binding of potential substrates 
the peptide sequence of the non-specific gelatinase sub-
strate 1 (M-2055)30 was minimised with respect to its ge-
ometry, and then docked into the MMPs. In order to vali-
date modelling work, attempts at crystallisation of this 
and other substrates were undertaken in order to deter-
mine the X-ray crystal structure. Crystallisation experi-
ments failed to yield suitable crystals for structure deter-
mination, therefore only CHARMM minimised geome-
tries of the substrates were employed throughout this 
study.  
Figure 1 shows the interaction of 1’s peptide sequence 
with human MMP-2 and MMP-9. In both MMPs the zinc 
ion interacts with the Gly and Cys(Me) bond, the known 
cleavage site according to Bickett et al.30  MMP-9 is able 
to bind tightly with the substrate residues compared to 
MMP-2, as determined by differences in their predicted 
inter-atomic zinc distances and overall binding energies. 
The substrate bound MMP-complexes provided crucial 
insight into the differences in their subsite interactions, as 
S1 and S3 subsites in MMP-2 demonstrated affinity to ac-
commodate longer side-chains than MMP-9. The charged 
nature of the S2 subsite (presence of His205) in MMP-2 
lends affinity for acidic residues, whereas this feature is 
not observed in MMP-9. In the MMP-9 structure, the car-
boxylic acid between Gly and Cys(Me) chelates the zinc 
ion (2.1 Å) and is involved in a strong H-bond to the car-
boxylate O of Glu402. The zinc ion is further coordinated 
by three Histidine residues namely His 401, His 405 and 
His 411 present in Helix αβ segment of the protein. Only 
the P1’ amino acid is involved in strong H-bonds with 
Arg424 (2.2 Å), which creates the wall-forming segment.  
The strong binding of Arg424 with the P1’ residue is an 
important determinant of the specificity pocket. Remain-
ing substrate residues are involved in strong interactions 
with the bulge-edge segment molecules (Gly186 to 
His190) with interatomic distances ranging from 2.5 to 3.1 
Å. The docked complex of 1 and MMP-9 has an overall 
binding energy of 706 kcal/mol (Figures 1 and S2). 
Consideration of the interaction of 1 with the active site of 
MMP-2 shows a marked reduction in affinity in energetic 
terms, the predicted interaction is seven times weaker  
 
 
Figure 1. (Left) Stereo view of the docked complexes of 1 
substrate (white sticks) and the catalytic domain of human 
MMP-2 (PDB ID: 1QIB) and MMP-9 (PDB ID: 1GKC). Catalyt-
ic and structural zinc ions are shown as purple spheres. Ac-
tive-site cleft residues (the αβ-helix loop and the specificity 
loop) are shown in green. (Right) Schematic representation 
of 1: active site binding interaction in human MMP-2 and 
MMP-9. MMP-2 and MMP-9 enzyme binding pockets are 
shown in red and green respectively. Substrate chemical 
structure and its scissile bond is shown in black. The zinc ion 
coordinated by histidine is indicated in blue.  
 than that of 1 and MMP-9 (binding energy of 101 
kcal/mol). Gly forms the P1 subsite and Cys(Me) forms 
the P1’ subsite and the presence of a zinc ion, chelated by 
the carboxylic acid between P1-P1’ residues (3.8 Å), further 
confirms this. The P1’ residue, although favourable for the 
MMP-2 specificity pocket, is not involved in any signifi-
cant interaction with MMP-2 residues. The remaining 
substrate residues have weak H-bond interactions with 
wall-forming and bulge-edge segments of MMP-2 with 
interatomic distances ranging from 3.1 to 5.1 Å. This is 
expected as 1 residues are oriented away from further 
MMP-2 binding pockets (Figure 1 and S2). Key observed 
differences between the binding affinity of MMP-2 and 
MMP-9 with 1 are: S1 and S3 subsites in MMP-2 can ac-
commodate longer side-chains than MMP-9. Charged 
nature of S2 subsite in MMP-2 has affinity for acidic resi-
dues, whereas this feature is not observed in MMP-9.  
To experimentally validate the predictability of this 
model, and confirm the in vitro cleavage position of 1, 
hydrolysis of the substrate by recombinant MMP-2 and 
MMP-9 was assessed over a 12 hour period.  The resultant 
products were analysed by LCMS using a reverse phase 
gradient system to separate the substrate 1 and proteolyt-
ic products. The identification of these species was con-
firmed by retention time and mass spectrometry (MS) 
data. 1 demonstrated a retention time (tR) of 2.8 minutes 
(Figure S3) and rapid cleavage  by MMP-9 at Gly-Cys(Me) 
bond was confirmed by LCMS, two peaks corresponding 
to Dnp-Pro-β-Cyclohexyl-Ala-Gly at tR of 2.3 minutes 
(m/z 491.5Da, [M+H]+) and Cys(Me)-His-Ala-Lys(N-Me-
Abz)-NH2 at tR of 2.47 minutes (m/z 604.7Da, [M+H]+) 
(Figures 2 and S4). Slow hydrolysis of 1 by MMP-2 (com-
pared to MMP 9) at Gly-Cys(Me) bond was confirmed by 
two peaks at tR of 2.3 minutes and tR of 2.47 minutes. 
MMP-2 cleavage experiments displayed a parent peak of 1, 
detected at tR of 2.8 minutes (m/z 1077.5Da, [M+H]+), 
suggesting that MMP-2 metabolised 1 at a slower rate 
than MMP-9 (Figures 2 and S5). This in vitro assessment 
supports the validity of the predicted in silico model of 
substrate and MMP interactions and was subsequently 
used for further design of MMP-targeted therapeutics. 
The next phase of the study was to design a prodrug 
(substrate and warhead) which would be selectively- 
 
 
 
Figure 2. Schematic representation of the cleavage of 1 sub-
strate by recombinant MMP-2 and MMP-9 enzymes at Gly-
Cys(Me).  
 
activated by a specific MMP over a close family homo-
logue i.e. MMP-2 not MMP-9. A known MMP-targeted 
peptide-conjugated doxorubicin prodrug31,32 was evaluated 
as it is cleaved by both MMP-2 and MMP-9, presenting an 
excellent model for further modification. MMP-targeted 
peptide-conjugates were synthesised via solid phase 
chemistry and purified by reverse phase HPLC, the 
chemotherapeutic drug doxorubicin conjugated to the C-
terminus (Scheme S6). Predicted in silico interaction of 
the 2 (reference compound) with MMP-2 and MMP-9 
shows the zinc ions are chelated by the carboxylate be-
tween Gly-Ser(O-Benzyl) bond (2.6 Å and 2.8 Å respec-
tively), the known cleavage site.31,32 Figure S7 shows the 
binding pockets of MMP-2 are larger and deeper than 
MMP-9, S1 subsite allowing for larger aromatic residues. 
The compound 2 aligns tightly into the active site of both 
MMPs as shown by their predicted interatomic zinc dis-
tances and binding energies (555 kcal/mol and 492 
kcal/mol) in MMP-2 and MMP-9 docked complexes re-
spectively. Active site residues interact with the com-
pound in a similar way to that previously explained. 
His205 in MMP-2 αβ-Helix loop makes the S2 pocket 
charged in nature and could potentially accommodate 
acidic residues (Figures S7 and S8). To experimentally 
validate the in silico docking of 231,32 and confirm the in 
vitro cleavage site, the lysis of this prodrug by recombi-
nant MMP-2 and MMP-9 was assessed over a 12 hour pe-
riod; with the resultant products being assessed by LCMS. 
HPLC (reverse phase gradient) was used to separate 2 
(Cbz-Glu-Pro-Leu-Gly-Ser(O-Benzyl)-Tyr-Leu-
Doxorubicin),31,32 identification confirmed by mass spec-
trometry (MS) with a retention time (tR) of 3.63 minutes 
(Figure S9). Cleavage of 2 by both MMP-2 and MMP-9 at 
Gly-Cys(Me) bond was confirmed by LCMS, two peaks 
corresponding to Cbz-Glu-Pro-Leu-Gly at tR of 2.87 
minutes (m/z 547.2Da, [M+H]+) and Ser(O-Benzyl)-Tyr-
Leu-Doxorubicin at tR of 3.23 minutes (m/z 997.4, 
[M+H]+). (Figures 3, S10 and S11). A parent peak was also 
detected at tR of 3.63 minutes (m/z 1525.8Da, [M+H]+). 
This in vitro assessment supports the predictability of in 
silico model of anticancer therapeutics with MMPs, for 
further design of MMP-2 selective prodrugs.  
 
 
Figure 3. Schematic representation of the cleavage of 2 by 
recombinant MMP-2 and MMP-9 enzymes at the Gly-Ser(O-
Bn) bond. 
 
A B
 Rational design of a peptide conjugate selective for MMP-
2 over MMP-9 was achieved by incorporating residues 
into the peptide chain to fit S1, S2, S3 and S1’ pockets of 
MMP-2 which differ in size and polar affinity compared to 
MMP-9. The following modifications were incorporated: 
Aromatic residues in S1 subsite; acidic side-chain in S2 
subsite and a polar side-chain at the S3 subsite. Small 
non-polar residues were included at the S1’ subsite despite 
S1’s potential to accommodate longer hydrophobic resi-
dues. This was due to longer residues leading to a nega-
tive effect on the predicted binding affinity, due to con-
formational alteration.  
 
Figure 4. (Left) Stereo view of docked complexes of 3 (white 
sticks), catalytic domain of human MMP-2 (PDB ID: 1GKC) 
(Red) and MMP-9 (PDB ID: 1GKC) (Green). Catalytic and 
structural zinc ions are shown as purple spheres and active-
site cleft residues (αβ-helix loop and the specificity loop) are 
shown as green. (Right) Schematic representation of 3 sub-
strate: active site binding interaction in MMP-2 and MMP-9, 
are shown in red and green respectively. Substrate chemical 
structure and its scissile bond is shown in black and zinc ion 
coordinated by histidine is indicated in blue.  
  
The zinc ion in MMP-2 demonstrated interaction with 3 
at carboxylate between Homophenylalanine (Hof)-Leu 
bond (1.9 Å), indicating the predicted cleavage site. Resi-
dues of MMP-2 tightly bind with 3 as demonstrated by 
strong interactions with the bulge-edge segment mole-
cules (Gly162 to His166) and the wall-forming segment 
molecules (Tyr223 to Thr229) with interatomic distances 
ranging from 1.8 to 2.8 Å. The docked complex of 2 and 
MMP-2 has an overall binding energy of 805 kcal/mol. In 
MMP-9 the zinc interaction is not detectable and the 
predicted binding energy is negative (-107 kcal/mol) sug-
gesting the modified peptide residues should give selec-
tivity of MMP-2 over MMP-9 (Figures 4 and S12). The hy-
drolysis of 3 by recombinant MMP-2 and MMP-9 was as-
sessed over a 12 hour period and analysed by LCMS. Re-
verse phase HPLC identified 3 at tR of 3.58 minutes (Fig-
ure S13). 3 was preferentially cleaved by MMP-2 at Hof-
Leu two peaks identified; corresponding to Leu-
Doxorubicin at tR of 2.078 minutes (m/z 657.2Da, 
[M+H]+) and Cbz-Gly-Pro-Ile-Gln-Glu-Hof at tR of 2.826 
minutes (m/z 821.4Da, [M+H]+) (Figures S14 and S15). 
Conversely MMP-9 did not cleave 3 in the same 
timeframe, indicating that 3 is MMP-2 selective support-
ing the in silico prediction (Figure S14).  
In order to assess efficacy and demonstrate proof-of-
concept for the developing approach, the effects of 3 were 
assessed against the U87-MG malignant human glioma 
cell line. This cell line is derived from a highly aggressive 
glioma tumour and expresses both MMP-2 and MMP-9 
(Figure 5). Cytotoxicity was observed in this cell line with 
doxorubicin, Leucine-doxorubicin (Leu-Dox) and 3, with 
IC50 values of 0.3±0.2 M, 0.6±0.2 M and 5.0±1.2 M, 
respectively. The differential cytotoxicity between doxo-
rubicin and 3 supports the requirement for 3 to be acti-
vated prior to inducing its effects. Furthermore, 3 re-
mained inactive in the presence of a pan-MMP inhibitor 
(GM6001; Ilomastat), demonstrating MMP-selective 
chemotherapeutic action of this prodrug. 
In order to further determine the tumour-selective acti-
vation of 3, its metabolism was studied ex vivo using 
MMP-expressing HT1080 human tumour xenograft33 and 
homogenized murine liver and kidney tissues (Figure 
S16). Rapid metabolism of 3 was observed in the HT1080 
xenograft homogenate (t½ = 9.8 minutes). In comparison, 
3 was relatively stable in murine liver (t½ = 17 minutes) 
and murine kidney (t½ = 38.5 minutes).  Metabolism of 3 
in HT1080 homogenates resulted in rapid production of 
the chemotherapeutic agent.  
  
 
Figure 5. Therapeutic efficacy of 3 against human cancer. A) 
Expression of MMP-2 and MMP-9 mRNA in the U87-MG 
glioma cell line; B) MMP-activity in the U87-MG cell line, as 
demonstrated by activation of the M2055 substrate; C) Cyto-
toxicity of doxorubicin, Leu-Dox and 3 against U87-MG cell 
line. MMP-selective activation of 3 in the presence of a pan-
MMP inhibitor (Ilomastat).  
CONCLUSIONS 
Targeted cancer therapies offer the potential of reduced 
side effects along with benefits of prolonging drug expo-
sure to cancerous tissues, enabling improved tumour re-
sponse and survival rates.34,35 Harnessing the elevated 
enzymatic activity of MMPs within the tumour microen-
vironment to selectively convert a non-toxic prodrug into 
a potent chemotherapeutic agent is one such approach 
with significant potential therapeutic scope.36,37 In this 
study a reiterative approach using in silico docking cou-
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 pled to in vitro biochemical proteolytic assessment have 
been applied to enable the development of anticancer 
prodrugs selectively activated by MMP-2, but not the 
close family homologue MMP-9. Proof-of-concept for this 
therapeutic approach was demonstrated against a glioma 
cell line in vitro, with the involvement of MMPs con-
firmed using pharmacological inhibition and by tumour-
selective activation with ex vivo tumour xenografts. This 
study has shown that it is feasible to utilise in silico pre-
dictive approaches to rationally design MMP-selective 
prodrugs with possible utility in the treatment of cancer.  
EXPERIMENTAL 
3D-Molecular Modelling 
All the molecular modelling and calculations were per-
formed using the BIOVIA Discovery Studio 4.0 molecular 
modelling package, developed by Accelrys. The X-ray 
crystal structure of proteins MMP-2 (PDB ID: 1QIB) and 
MMP-9 (PDB ID: 1GKC) were acquired from the Protein 
Data Bank (PDB) and prepared by omitting the ligands 
associated with the co-crystal structure. Substrate ligand 
structures were prepared in Avogadro and converted to 
Discovery studio in MOL format. Using the ‘Receptor-
Ligand Interactions’ tool, the substrate 3D-structures 
were optimised by complete energy minimisations using 
the CHARMM (Chemistry at Harvard Macromolecular 
Mechanics) force field (using 10000 minimisation cycles) 
and prepared for flexible receptor-ligand docking (refer to 
Figure S17 for 3D structure of MMP-9 demonstrating the 
adaptation of Zn+2 before and after flexible docking). The 
substrate ligands were docked into the active site clefts of 
MMPs via flexible docking, wherein the protein structure 
was selected as the ‘receptor molecule’ and the substrate 
structures as the ‘ligand molecule’. Docking results were 
analysed in Discovery Studio by viewing the ligand inter-
actions, hydrophobic receptor surfaces and the location of 
zinc ion in the receptor with respect to the ligand. The 
binding free energies between a receptor and a ligand 
were also calculated using the CHARMM implicit solva-
tion models. The binding energy was calculated using the 
following equation: 
Energy binding = Energy complex – Energy ligand - Ener-
gy receptor (in kcal/mol) 
 
Synthesis of MMP-targeted peptide conjugates 
Custom designed peptide sequences with Cbz 
(Benzyloxycarbonyl) as the chemical endcap were sup-
plied (Bachem, Switzerland)/ synthesised using solid 
phase strategy. Activation of the pre-loaded 2-chlorotrityl 
resin was carried out in a fritted polypropylene reaction 
chamber. 0.1mmol of resin was weighed into the reaction 
chamber and 2 ml of dry DCM added. The reaction vessel 
was shaken for 45 minutes. After this time, DCM removed 
and the resin washed further with DCM. Single couplings 
were carried out using 5 equivalents of peptide (compared 
to resin), 5 equivalents of benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP®), 10 equivalents of N,N-Diisopropylethylamine 
(DIPEA) and 2 ml of DMF under agitation for 45 minutes. 
Double peptide couplings were carried out- 2 x 45 minute 
couplings for each residue addition- the reaction drained 
after each coupling and fresh reagents added. After each 
set of coupling reactions, the reaction solution was 
drained and resin washed with 5 portions of 2 ml DMF. 
Removal of the Fmoc group was carried out using 5 ml of 
a solution of 20% piperidine in DMF for 5 under agitation. 
Piperidine solution was drained and fresh solution added 
for a further 10 minutes under agitation. Piperidine solu-
tion was drained and the resin rinsed using 5 portions of 2 
ml DMF. Peptide-resin was treated with a solution of 20% 
hexafluoroisopropanol in DCM for 1 hour. The resin was 
removed by filtration and the solvent removed from the 
filtrate under reduced pressure before precipitation using 
ether and decanting of the liquid (followed by subsequent 
ether washes). The resulting solid peptide (Cbz-
GPIQ(Trt)-E(tBu)-hPhe-L-OH) was dissolved in deion-
ized water and acetonitrile mix and lyophilized. Purifica-
tion of peptides was carried out using Perking Elmer 
HPLC. Samples were injected into a column and a gradi-
ent of 0-100% solvent B (solvent A= 95% H2O, 5% MeCN, 
0.01% TFA, solvent B = 95% MeCN, 5%H2O, 0.01% TFA) 
over 95 minutes with a flow rate of 2.0 ml/min. Doxorubi-
cin was conjugated to the peptide C-terminus as follows: 
Doxorubicin.HCl (0.0012 g, 0.002 mol, 1 equiv.), peptide 
(0.0022 g, 0.002 mol, 1 equiv.), PyBOP® (0.0015 g, 0.003 
mol, 1.3 equiv.), and hydroxybenzotriazole hydrate 
(0.0073 g, 0.0054 mol, 2.6 equiv.) were added together 
under nitrogen in anhydrous DMF (2 mL). DIPEA (8 
equiv., 0.016 mol) was added and the reaction mixture 
was stirred overnight in the absence of light. Solvent was 
removed in vacuo and the mixture triturated with cold 
Et2O (5 mL) to precipitate the crude peptide which was 
then obtained through centrifugation to obtain the crude 
solid peptide conjugate.  The product was then purified 
using a C18 column and reverse phase HPLC 
(H2O/MeCN) gradient system using  mass spectrometry 
as confirmation of molecular mass to give a pale red solid 
(0.0021 g, 70 % yield). 
Liquid Chromatography and Mass Spectrometry (LCMS) 
detection of substrates 
LC conditions: High-purity HPLC-grade solvents (Sig-
ma-Aldrich), analytical grade chemicals (Sigma-Aldrich) 
and triple distilled water were used throughout. Reverse-
phase chromatographic separation of substrates was per-
formed using an Acquity UPLC comprising a BEH C18 
1.7µM column (2.1mm x 100mm) (Waters, UK).Mobile 
phases were as follows: Mobile Phase A consisted of 90% 
HPLC grade water, 10% HPLC grade MeCN and 0.1% 
HCO2H. Mobile phase B consisted of 40% HPLC grade 
water, 60% MeCN and 0.1% HCO2H. 
MS conditions: A Micromass ZMD single quadrupole 
electrospray MS was used in positive mode (Micromass, 
Manchester, UK) and MassLynx software was used to 
identify substrates and anticipated metabolites. MS 
source parameters were optimised to: desolvation gas 375 
L/hr, cone gas 33 L/hr, capillary 2.9 kV, sample cone 16V, 
 extraction cone 5V, fR lens 0.1V, source block temperature 
150°C and desolvation temperature 200°C. Parent com-
pounds and metabolites were detected as singularly 
charged ions using selected ion readings (SIR). 
 
Cleavage of substrates by recombinant MMPs 
Recombinant human MMP proteins (MMP-2 and 
MMP-9, R&D Systems, UK) were assayed for their ability 
to cleave MMP-selective substrate 1, and peptide conju-
gates. Reactions (100 µL) contained 20 ng recombinant 
protein and 10 µM substrate in MMP activity buffer (100 
mM Tris-HCl pH 7.6, 10 mM CaCl2, 100 mM NaCl, 0.16% 
v/v Brij-35), and incubated at 37˚C for 12h. At T12, The 
sample was removed and diluted 1:3 with MeCN to precip-
itate proteins. The sample was then centrifuged at 10,000 
g for 3 minutes and supernatant assayed for substrate 
cleavage by LCMS. 
 
Determination of MMP mRNA expression by semi-
quantitative RT-PCR analysis 
   Refer to section S18. 
 
MTT assay 
Drug cytotoxicity was evaluated against the human 
U87-MG glioma cell line. Cells were seeded into 96-well 
plates at 2000 cells/well. After 24 h incubation, cells were 
treated with various concentrations of compound or rele-
vant vehicle control. Following a further 96 h drug expo-
sure, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium Bromide) (500 µg/well) was added 
and incubated for 4 h at 37°C. MTT was carefully re-
moved, the blue formazan crystals dissolved in DMSO), 
and absorbance measured at 550 nm (GO Multiskan, 
Thermo Life Sciences). Cell survival was normalised to 
vehicle treated control wells, which represented 100% 
viability (data representative of three independent exper-
iments).  
 
Metabolism of 3 in tissues ex vivo 
   Refer to section S19. 
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